Carcinomas News and Research

RSS

New study suggests potential use of targeted therapies for two subtypes of esophageal cancer

Nearly all advanced esophageal cancers harbor genetic mutations that can be targeted with emerging drug therapies, according to a new study published in The Oncologist on September 2, 2015.

3 Sep 2015

MACC1 gene can help predict better treatment options for patients with Klatskin carcinoma

Bile duct cancer is rare and is usually detected too late. Often only extensive liver surgery can help or, in rare cases, liver transplantation. But which patients will benefit from surgery and which will not, because their risk of cancer recurrence is too high? With the oncogene MACC1 as a biomarker, physicians for the first time have a tool to decide which treatment option is best for patients with Klatskin carcinoma, one type of bile duct cancer.

1 Sep 2015

Researchers identify new virus that plays role in rare type of liver cancer

More than a cause of a simple infection, viruses are often involved in the development of serious diseases. Such is the case with liver cancer, which often develops in an organ that has been weakened by hepatitis B or C virus.

28 Aug 2015

HPPI commences enrollment for Phase II(b) SCORING clinical trial for cancer treatment

HedgePath Pharmaceuticals, Inc., a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today enrollment has commenced in its Phase II(b) SCORING (SUBA-Cap Objective Response in Gorlin's) clinical trial.

23 Aug 2015

Meta-analysis confirms oral contraceptives reduce endometrial cancer risk

Oral contraceptive use protects against endometrial cancer, with effects persisting for decades after cessation of use, shows a meta-analysis of individual patient data published in The Lancet Oncology.

10 Aug 2015

One sunburn increases risk of skin cancer by 50%

Everybody's got a story about that "one bad burn" - the time you fell asleep next to the pool and tattooed a white handprint on your lobster-red chest, or forgot to pack the sunscreen while hiking a Colorado 14er.

30 Jul 2015

New surgical method preserves long-term renal function following removal of renal tumours

Renal cell carcinomas are one of the most common types of cancer. In order to preserve its wide range of functions, every effort is made not to remove the entire kidney, but rather just a portion of it. A surgical method that preserves long-term renal function has now been carried out successfully for the first time in the Department of Urology at the MedUni Vienna and Vienna General Hospital.

13 Jul 2015

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

Today AbbVie announced the European Commission granted marketing authorization for IMBRUVICA (ibrutinib) as the first treatment option available in all 28 member states of the European Union for the treatment of Waldenstrom's macroglobulinemia (WM), a rare, slow growing blood cancer, in adult patients who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.

12 Jul 2015

Breast tumors have something in common with embryos, say MD Anderson researchers

It may seem incredulous, but breast tumors may have something in common with embryos ... at least in mice, say researchers at The University of Texas MD Anderson Cancer Center.

1 Jul 2015

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Eli Lilly and Company announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial's primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant.

19 Jun 2015

Study highlights discovery of genetic variants linked to mucinous ovarian carcinomas

New research by an international team including Keck Medicine of USC scientists is bringing the origins of ovarian cancer into sharper focus.

16 Jun 2015

CASI files application with CFDA to conduct ENMD-2076 Phase 2 trial in fibrolamellar carcinoma patients

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announced today that it has filed an application with China's Food and Drug Administration to conduct a Phase 2 clinical trial in fibrolamellar carcinoma (FLC) patients in China for its proprietary drug candidate, ENMD-2076.

4 Jun 2015

Investigators patent novel technique for detecting carcinomas in oral mucosa

Malignant tumours of the oral cavity are the sixth leading cause of cancer-related deaths worldwide. As such, a fast and accurate diagnosis is key to maximising the probability of successful treatment and the hope and quality of life of patients.

4 Jun 2015

Phase 2 results from Abbvie’s veliparib study in NSCLC presented at ASCO 2015

AbbVie, a global biopharmaceutical company, today announced findings from a Phase 2 study of the investigational medicine veliparib combined with the chemotherapy regimen carboplatin and paclitaxel that showed an improvement in median progression-free survival (PFS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC) who are current smokers.

2 Jun 2015

Caris Life Sciences: Study identifies benefit of targeted therapy in CRC with high microsatellite instability

Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the results of a study identifying the clinical benefit of targeted therapy in colorectal cancer (CRC) with high microsatellite instability (MSI-H), a predisposition that occurs in 15% of all CRCs causing significantly different prognosis and response to treatment.

1 Jun 2015

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics LLC today highlighted results from a sub-analysis of the Phase III RESONATE™ (PCYC-1112) trial, which found that previously-treated patients with chronic lymphocytic leukemia (CLL) who adhered to the recommended 420 mg dose of IMBRUVICA® (ibrutinib) experienced improved progression-free survival (PFS; the primary endpoint) as assessed by an Independent Review Committee (IRC), compared to patients who took lower doses or missed doses, regardless of high-risk genetic factors.

1 Jun 2015

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent.

1 Jun 2015

Clinical utility of Caris Molecular Intelligence in five studies to be presented at ASCO 2015

Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the presentation of data from five studies that demonstrate the clinical utility of Caris Molecular Intelligence®, the company's panomic comprehensive tumor profiling service, in helping to identify targeted treatment options for patients with rare and/or aggressive tumors.

1 Jun 2015

Caris Molecular Intelligence allows comparisons between tumors sharing histological features

Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the presentation of data from three studies that demonstrate the utility of Caris Molecular Intelligence®, the company's panomic comprehensive tumor profiling service, in facilitating comparisons between tumors that share histological features.

1 Jun 2015

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Today, Pharmacyclics LLC announced the results of the Phase III HELIOS trial (CLL3001), which found that patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who received ibrutinib (IMBRUVICA) in combination with bendamustine and rituximab (BR) experienced an 80% reduction in the risk of progression or death compared to patients receiving placebo in combination with BR.

1 Jun 2015

Carcinomas News and Research

New study suggests potential use of targeted therapies for two subtypes of esophageal cancer

MACC1 gene can help predict better treatment options for patients with Klatskin carcinoma

Researchers identify new virus that plays role in rare type of liver cancer

HPPI commences enrollment for Phase II(b) SCORING clinical trial for cancer treatment

Meta-analysis confirms oral contraceptives reduce endometrial cancer risk

One sunburn increases risk of skin cancer by 50%

New surgical method preserves long-term renal function following removal of renal tumours

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

Breast tumors have something in common with embryos, say MD Anderson researchers

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Study highlights discovery of genetic variants linked to mucinous ovarian carcinomas

CASI files application with CFDA to conduct ENMD-2076 Phase 2 trial in fibrolamellar carcinoma patients

Investigators patent novel technique for detecting carcinomas in oral mucosa

Phase 2 results from Abbvie’s veliparib study in NSCLC presented at ASCO 2015

Caris Life Sciences: Study identifies benefit of targeted therapy in CRC with high microsatellite instability

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Clinical utility of Caris Molecular Intelligence in five studies to be presented at ASCO 2015

Caris Molecular Intelligence allows comparisons between tumors sharing histological features

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News